Sector: Biotechnology
Platform: StartEngine
Stage: Early
Minimum Investment: $500
What They Do
Calosyn Pharma is developing a non-steroidal therapy for autoimmune skin diseases such as psoriasis and eczema.
Why It Might Be the Next Big Thing
Patients need safer, more sustainable alternatives to steroids. Calosyn’s candidate targets the inflammation pathways directly — without immunosuppressive downsides.
Snapshot
Preparing for FDA Phase I
Biotech founders with prior exits
Positive preclinical efficacy results
My Take
The dermatology market is ripe for disruption. Calosyn could be one to watch if its early data translates in humans.
📖 Disclaimer: This newsletter is for informational purposes only and does not constitute financial advice or investment solicitation.